Mechanism-based medication development for the treatment of nicotine dependence

Zheng-xiong XI*, Krista SPILLER, Eliot L GARDNER

Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Baltimore, MD 21224, USA

Tobacco use is a global problem with serious health consequences. Though some treatment options exist, there remains a great need for new effective pharmacotherapies to aid smokers in maintaining long-term abstinence. In the present article, we first discuss the neural mechanisms underlying nicotine reward, and then review various mechanism-based pharmacological agents for the treatment of nicotine dependence. An oversimplified hypothesis of addiction to tobacco is that nicotine is the major addictive component of tobacco. Nicotine binds to α4β2 and α7 nicotinic acetylcholine receptors (nAChRs) located on dopaminergic, glutamatergic and GABAergic neurons in the mesolimbic dopamine (DA) system, which causes an increase in extracellular DA in the nucleus accumbens (NAc). That increase in DA reinforces tobacco use, particularly during the acquisition phase. Enhanced glutamate transmission to DA neurons in the ventral tegmental area appears to play an important role in this process. In addition, chronic nicotine treatment increases endocannabinoid levels in the mesolimbic DA system, which indirectly modulates NAc DA release and nicotine reward. Accordingly, pharmacological agents that target brain acetylcholine, DA, glutamate, GABA, or endocannabinoid signaling systems have been proposed to interrupt nicotine action. Furthermore, pharmacokinetic strategies that alter plasma nicotine availability, metabolism and clearance also significantly alter nicotine’s action in the brain. Progress using these pharmacodynamic and pharmacokinetic agents is reviewed. For drugs in each category, we discuss the mechanistic rationale for their potential anti-nicotine efficacy, major findings in preclinical and clinical studies, and future research directions.

Keywords: nicotine; reward; addiction; smoking cessation

Acta Pharmacologica Sinica (2009) 30: 723–739; doi: 10.1038/aps.2009.46; published online 11 May 2009

Introduction

Nicotine use and dependence is a world-wide health problem. In the United States alone, approximately 45 million people smoke cigarettes and the adverse health effects from cigarette smoking account for an estimated half million deaths each year[1]. Though many cigarette smokers report a desire to quit smoking, few are successful. In fact, according to the US Department of Health and Human Services, approximately 80% of smokers who attempt to quit relapse before achieving 6 months of abstinence. Of the remainder, relapses may occur years after a smoker initially quits[2]. Consequently, there is a great need for pharmacotherapies to aid smokers who wish to quit.

Although the mechanisms underlying tobacco addiction are not completely understood, accumulating evidence indicates that nicotine is the major addictive component[3,4]. In preclinical experimental conditions, nicotine produces many hallmark behaviors observed with other addictive drugs. Non-contingent administration of nicotine stimulates locomotor activity[5,6] and enhances electrical brain-stimulation reward[7]. It can also reinforce intravenous self-administration[3,8], produce conditioned place preference[9], and serve as a discriminative stimulus in animals[10]. In addition, nicotine cessation produces withdrawal syndromes with both somatic and affective symptoms[4,11], and those symptoms can be alleviated by nicotine replacement.

Neural mechanisms underlying nicotine dependence

Nicotinic acetylcholine receptors (nAChRs) Nicotine is an alkaloid that binds to central and peripheral nicotinic acetylcholine receptors (nAChRs). Acetylcholine (ACh) is
an endogenous neurotransmitter that binds to and activates nAChRs. Neuronal nAChRs are ligand-gated ion channels with high permeability to Ca$$^{2+}$$, and are formed from combinations of five subunits$^{[12,13]}$. To date, twelve different neuronal nAChR subunits have been cloned, including nine α-subunits (α2–α10) and three β-subunits (β2–β4). Non-neuronal subunits, α1, β1, γ, δ, and ε, form peripheral nicotinic receptors at the neuromuscular junction$^{[14]}$. The neuronal subunits combine with a stoichiometry of two α- and three β-, or five α7-subunits to form nAChRs$^{[15]}$. Both the α4β2 and a7 subtypes of nAChRs are the most abundant subtypes in the brain and are localized on presynaptic terminals, axons, somatodendrites or on postsynaptic cells$^{[16,17]}$. Overall, activation of presynaptic nAChRs by ACh or nicotine potentiates neurotransmitter release, while activation of postsynaptic nAChRs increases excitability of postsynaptic cells by increasing Ca$$^{2+}$$ influx via nAChR channels.

**ACH-glutamate-GABA-DA mechanisms underlying nicotine dependence** Although many areas of the brain are involved in reward, the mesocorticolimbic dopamine (DA) system serves a vital and fundamental role in mediating the rewarding and psychostimulant effects of addictive drugs, including nicotine$^{[9,18]}$. This system originates from DA neurons in the ventral tegmental area (VTA) in the midbrain and projects to the nucleus accumbens (NAc), the amygdala and the prefrontal cortex$^{[18]}$. The activity of VTA DA neurons is regulated by excitatory glutamatergic inputs predominantly from the prefrontal cortex, cholinergic inputs from brainstem nuclei and inhibitory GABAergic inputs within the VTA or from the NAc (Figure 1). This DA model is supported by a number of findings$^{[8,19]}$. For example, nicotine self-administration elevates NAc DA, and that elevation reinforces nicotine self-administration, particularly during the acquisition phase$^{[20]}$. In contrast, chemical lesion of DA terminals or pharmacological blockade of DA receptors in the NAc attenuates the rewarding effects of nicotine, as indicated by reduced self-administration$^{[8,21]}$.

Several studies suggest that the α4β2 nAChR subtype plays a major role in nicotine reward. First, pretreatment with the selective α4β2 receptor antagonist dihydro-β-erythroidine (DHβE) or the partial agonist SSR591813 significantly inhibits nicotine self-administration in rats$^{[22,23]}$. Similarly, genetic deletion of β2 subunits abolishes nicotine self-administration$^{[24]}$. Second, in vivo microdialysis studies indicate that the selective α4β2 receptor partial agonist SSR591813 or genetic deletion of α4 or β2 subunits prevents nicotine-induced increase in NAc DA$^{[23,25]}$. Third, nicotine-mediated currents from VTA neurons are inhibited by DHβE$^{[24,26–28]}$ or dramatically decreased on midbrain neurons in β2-null mice$^{[24,28]}$. Fourth, brain slices from α4- or β2-subunit knockout mice lack high-affinity nicotine binding, confirming that most (if not all) binding sites for nicotine in adult brains contain α4β2-containing receptors$^{[24,29]}$. These data suggest that both α4 and β2 subunits in the VTA are crucial in mediating nicotine’s DA-releasing effects. Thus, the effects of nicotine on DA function could be mediated by activation of α4β2 nAChRs located on DA neurons in the VTA and on DA terminals in the NAc$^{[30]}$.

In addition, several studies suggest the involvement of other nAChR subunits, including α3, α6, α7, and β3, in the control of DA release induced by nicotine. It was reported that α7 nAChRs are also expressed on VTA DA neurons$^{[31,32]}$, and nicotine still activates midbrain neurons in β2-subunit knockout mice by a α7-nAChR mediated mechanism$^{[28]}$, suggesting the involvement of α7 nAChRs in nicotine’s action. Differential distribution of nAChR subtypes has been found on glutamatergic (α7) and GABAergic (α4β2) terminals in the VTA$^{[27,28,33]}$. Different nAChR subtypes appear to show different levels of desensitization: the α4β2 subtype desensitizes more rapidly than the α7 subtype$^{[32]}$. Therefore, it has been proposed that nicotine first activates then desensitizes α4β2 nAChRs on VTA DA neurons, producing an initial fast increase in extracellular DA in the NAc$^{[12,24,26]}$. At the same time, nicotine also excites α7 nAChRs located on presynaptic glutamatergic terminals and increases excitatory glutamatergic inputs to VTA DA neurons. Since the α7 nAChRs have much lower affinity for nicotine than α4β2 nAChRs, and are therefore much less susceptible to desensitization by low concentrations of nicotine obtained from tobacco smoking, the enhanced glutamate release causes prolonged DA neuron activation$^{[34]}$. In addition, nicotine may also excite α4β2 receptors located on VTA GABAergic neurons to increase GABA release$^{[33]}$. Thus, the DA-releasing effects of nicotine may result from a modification of the balance between excitatory and inhibitory inputs to DA neurons$^{[12,26,36]}$. This hypothesis may in part explain the finding with in vivo microdialysis that a single injection of nicotine produces long-term (2 h) increases in extracellular NAc DA$^{[9]}$.

It should be pointed out that not all evidence supports this hypothesis. For example, conflicting findings were found in mutant mice lacking the α7 receptors or in rats injected with the relatively selective α7 nAChR antagonist methyllycaconitine$^{[37,38]}$. Although much attention has focused on the VTA-NAc pathway, many other brain sites that are not yet extensively studied are also likely to contribute to nicotine reward and addiction.

**Chronic nicotine-induced neuroadaptations** Most smokers report that the first cigarette of the day produces the
most powerful effects\textsuperscript{[39]}, suggesting that fast tolerance and desensitization develop after repeated exposure to nicotine. This could be related to findings that chronic exposure to nicotine results in fast desensitization of α4β2 nAChRs, leading to upregulation of α4β2 nAChRs on the cell surface\textsuperscript{[12, 28, 40–42]}. On the other hand, repeated administration of nicotine is also associated with sensitization, an effect that appears to be mediated (at least with respect to locomotor sensitization) by α4β2 subunits\textsuperscript{[23, 43]}. Sensitization of the motivational effects of nicotine is also seen in the self-administration and conditioned place preference paradigms\textsuperscript{[44, 45]}. These neuroadaptations may contribute to the development of nicotine addiction\textsuperscript{[36]}.  

**Animal models of nicotine dependence**

Animal models of addiction are, by definition, approximations of human drug abuse. A major obstacle to the development of medication for nicotine dependence is the lack of animal models with sufficient predictive clinical validity, and therefore, multiple animal models have to be used to emulate different aspects of nicotine dependence in humans. Six behavioral animal models or measures have been widely used in research on nicotine dependence. More details for each class of pharmacological agents are discussed in the text of this review.

**Self-Administration** Drug self-administration reliably models drug reinforcement\textsuperscript{[46]}. In this model, laboratory animals are allowed to operantly self-administer addictive drugs, such as nicotine. Two commonly used self-administration paradigms are fixed-ratio (FR) and progressive-ratio (PR) schedules of drug reinforcement. In the FR paradigm, a drug infusion follows after a fixed number of responses by the animal, eg, after every one (FR1) or two (FR2) lever presses. In the PR reinforcement paradigm, a progressively increasing work-load (eg, lever pressing) is imposed upon the animal in...
order to receive one drug administration. Eventually, a point is reached at which the animal stops responding. This is termed the PR “break-point” and is considered a measure of rewarding efficacy[47].

Reinstatement of drug-seeking behavior Nicotine dependence is characterized by high rates of relapse to tobacco use. The reinstatement animal model is widely used to model relapse to tobacco use in humans[48]. In this model, rats are implanted with intravenous catheters and are allowed to self-administer nicotine until stable nicotine-taking is achieved. Then, vehicle is substituted for nicotine. Since the animals are no longer rewarded, they stop (“extinguish”) the nicotine-seeking behavior. Next, the experimenter administers a stimulus to “trigger” the animal to relapse — to go back to the drug-seeking behavior that previously resulted in intravenous infusions of nicotine. Three triggers cause relapse in this model: 1) re-exposure to nicotine, 2) re-exposure to environmental cues that were previously associated with nicotine self-administration, or 3) exposure to mild stress. The face validity of the reinstatement models rest upon the fact that these are the triggers that provoke relapse to tobacco use in humans[46].

Conditioned Place Preference (CPP) The CPP model is an experimental procedure to study the rewarding effects of nicotine and/or reward-related learning and memory. In this model, a distinctive environment (in wall color, light, floor texture) in one compartment of a two- or three-compartment apparatus is paired repeatedly with nicotine or vehicle injections. CPP occurs when repeated nicotine administration in one particular environment results in the ability of previously neutral environmental stimuli to elicit approach behavior and increased time spent in that environment even in the absence of nicotine administration. It has been argued that CPP, like self-administration and several other behavioral measures, is an example of DA-mediated incentive learning and memory, and that the approach behavior and increased time spent by animals in nicotine-paired environment can be considered a measure of nicotine-seeking behavior[49].

Drug discrimination Drug discrimination procedures are often used as animal models for the subjective effects of an addictive drug[46]. The animal is trained to make one response when nicotine is given and a different response when vehicle is given. Well-trained animals typically make close to 100% appropriate responses to discriminate nicotine from vehicle. The degree to which a novel drug is perceived by the animal as “nicotine-like” versus “not-nicotine-like” is reflected in the percentage of nicotine-associated responses versus vehicle-associated responses. By combining a novel drug (e.g., a putative anti-nicotine therapeutic agent) with nicotine in this paradigm, one can determine the degree to which the novel drug increases or decreases the subjective “nicotine-like” feeling experienced by the animal.

Brain stimulation reward Virtually all addictive drugs not only have rewarding actions of their own, but also potentiate the rewarding actions of other substances or events[50]. The brain stimulation reward (BSR) paradigm models this property of addictive drugs by directly assessing the degree of drug-induced enhancement of BSR in animals trained to respond for electrical stimulation of specific brain-reward loci such as the VTA, medial forebrain bundle, or NAc. To assess drug-induced enhancement of BSR, the “rate-frequency curve-shift” paradigm is commonly used to measure changes in BSR thresholds after drug administration. Addictive drugs (such as nicotine) produce highly characteristic leftward shifts (e.g., decreased BSR threshold) in these functions, indicating summation between the reward provided by the electrical stimulation and the drug-induced reward. This paradigm is therefore useful in the search for compounds with potential anti-addictive therapeutic properties and, conversely, to screen compounds for reward-enhancing properties, which might be predictive of intrinsic addictive potential[46].

Withdrawal Many tobacco smokers report that they experience unpleasant withdrawal symptoms when they quickly quit smoking. In experimental animals, abrupt cessation of chronic nicotine or administration of nAChR antagonists causes somatic withdrawal symptoms, such as shakes/tremors, gasps/writhes, teeth chattering and ptosis[51, 52], which may in part mimic withdrawal symptoms experienced by abstinent smokers[53]. In addition, nicotine withdrawal also results in reduced DA overflow in the NAc[54] and elicits changes in behavior that are characteristic of anhedonia[11]. BSR, described above, can also be used to measure nicotine withdrawal-induced anhedonia[56, 46]. These changes are thought to model the dysphoria experienced by many smokers when they first quit[55]. Strikingly, all these symptoms can be reversed by nicotine replacement therapy[11]. Thus, relieving nicotine withdrawal symptoms, thought to be an important reason for relapse to tobacco use, may be another strategy to aid cessation of tobacco smoking.

Mechanism-based medication discovery

Although several types of pharmacological therapies have been approved for smoking cessation in both North America and Europe, long-term abstinence rates are less optimal. These approved pharmacological therapies include
nicotine replacement, the antidepressant bupropion and the α4β2 receptor partial agonist varenicline. The efficacy of bupropion and varenicline for smoking cessation has raised questions about how a non-nicotine drug can aid in smoking cessation. Here we review recent progress on *mechanism*-based medication strategies for the treatment of nicotine dependence at both preclinical and clinical levels. These strategies include various pharmacological agents that target brain ACh, DA, glutamate, GABA and endocannabinoid transmission, and pharmacokinetic approaches that alter blood nicotine concentrations, metabolism and clearance.

**ACh-based medication development**

*Nicotine replacement* Nicotine replacement therapy (NRT) is an early pharmacotherapy approved in the early 1980s for smoking cessation[56]. The rationale for NRT is similar to that for methadone or buprenorphine for the treatment of opiate dependence. That is, NRT uses safe delivery forms of nicotine to replace the nicotine obtained from cigarettes, thereby eliminating tobacco smoking and tobacco-related illnesses. Various NRTs are currently available and include gums, transdermal patches, lozenges, tablets, and inhalers. NRTs have been shown to be effective in aiding abstinence from cigarette smoking behavior, reducing the rewarding effects produced by nicotine from cigarettes, attenuating affective and somatic withdrawal symptoms, relieving craving and reducing relapse risk. However, efficacy is low and only lasts for a short period of time. At best only about 20% of smokers are able to maintain long-term abstinence with any of these approaches, and first year relapse rates are as high as 80%. The reasons underlying such low efficacy of NRTs are unclear, but likely to be related to their relatively poor pharmacokinetic properties compared to nicotine delivered via smoking. Thus, much research has been directed to develop other non-nicotine strategies for the facilitation of smoking cessation.

*Nonselective nAChR antagonists* In theory, a nonselective nAChR antagonist would block the physiological and reinforcing effects of cigarette smoking, and thereby lead to extinction of cigarette smoking behavior. A possible side-effect is that an antagonist may precipitate withdrawal symptoms, and thus increase the risk of relapse to cigarette smoking.

*Mecamylamine* Mecamylamine is a non-competitive nicotinic antagonist, originally used as an antihypertensive agent[57]. Widely used in the 1950s, this orally effective antihypertensive agent is now rarely used because of its widespread ganglionic side-effects at antihypertensive doses. However, recent studies suggest that mecamylamine, at relatively low doses, significantly attenuates the physiological and rewarding effects of nicotine, and improves abstinence rates in smoking cessation studies, particularly for women[58]. In particular, mecamylamine, when combined with NRT, significantly reduces craving for cigarettes and produces prolonged abstinence rates (37.5% versus 4.2% for 12 months) when compared with NRT alone[59]. Preclinical studies demonstrate that mecamylamine attenuates intravenous self-administration of nicotine[5,60,61], reduces nicotine-enhanced brain-stimulation reward[62], blocks nicotine-conditioned place preference[63], and inhibits the stimulant effect of nicotine on locomotor activity[64]. In contrast, it has also been reported that mecamylamine causes an increase rather than a decrease in smoking behavior, likely a compensatory response to partially reduced nicotine reward[65]. Further, a recent study did not find an added benefit of combining mecamylamine with use of a transdermal nicotine patch[66]. Thus, further studies are required to confirm mecamylamine’s efficacy for smoking cessation. Mecamylamine is currently in Phase III clinical trials in the United States, and is not yet approved by the US Food and Drug Administration (FDA) for smoking cessation.

*nAChR partial agonists* Given the central role of α4β2 nAChRs in nicotine reward as noted above, modulating the activity of these receptors is expected to have therapeutic benefits. Partial agonists, by definition, have lower intrinsic functional activity, and therefore, produce a smaller maximal effect at full receptor occupancy than do full agonists. By mimicking some of the agonist rewarding effects of nicotine, partial α4β2 nAChR agonists should, theoretically, relieve craving and withdrawal symptoms during abstinence. In addition, high affinity α4β2 nAChR partial agonists may also prevent nicotine binding to α4β2 nAChRs, therefore producing an “antagonistic” anti-nicotine effect. These considerations prompted the search for ligands that act as partial agonists at the α4β2 nAChR subtype of as novel treatments for smoking cessation.

*Varenicline* Varenicline is a partial agonist at α4β2 and a full agonist at α7 nicotinic receptors[67,68]. Both chemically and pharmacologically, varenicline is similar to cytisine, a plant alkaloid with high affinity for several subtypes of nAChRs[69]. Cytisine has been used in Eastern Europe for over 40 years as a treatment for tobacco dependence in the form of an extract from the herb Cytisus Laborinum L (Golden Rain acacia)[70]. In 1994, it was reported that cytisine is a weak partial agonist at nAChRs with limited absorption into the brain[71], providing an additional rationale for the use of partial agonists for smoking cessation. Direct chemical modifications of cytisine have lead to two novel highly potent and selective α4β2 nAChR partial ago-
nists-varenicline and dianicline. Varenicline, developed by Pfizer Inc, has been approved by the US FDA as a therapeutic aid to quit smoking, while dianicline, developed by Sanofi-Aventis, is currently under Phase III clinical trials. Preclinical studies demonstrate that varenicline elevates extracellular DA in the shell of the NAc, an effect that is weaker than that evoked by nicotine. Pretreatment with varenicline significantly inhibits nicotine-enhanced NAc DA and nicotine self-administration. Varenicline itself partially substitutes for nicotine in animal self-administration paradigms and partially generalizes to nicotine as a discriminative stimulus. Consistent with these findings, we have recently reported that varenicline also significantly inhibits nicotine-enhanced electrical brain-stimulation reward, an effect that is mediated by activation of a4β2, but not a7, nAChRs. It has also been reported that varenicline significantly reduces ethanol, but not sucrose, self-administration, and decreases voluntary ethanol, but not water, consumption in rats. Clinical trials indicate superior efficacy of varenicline over placebo and bupropion for achieving abstinence and nicotine self-administration. Varenicline itself inhibits nicotine-enhanced electrical brain-stimulation reward, an effect that is mediated by activation of α4β2, but not α7, nAChRs. It has also been reported that varenicline significantly reduces ethanol, but not sucrose, self-administration, and decreases voluntary ethanol, but not water, consumption in rats. Clinical trials indicate superior efficacy of varenicline over placebo and bupropion for achieving abstinence from smoking, and varenicline has also been shown to significantly delay smoking relapse. The safety profile of varenicline is generally good, with the most commonly occurring adverse event being nausea. However, new safety warnings were added to the varenicline label in early 2008 because of post-marketing reports of neuropsychiatric symptoms including agitation, depression and suicidality. A causal relationship between varenicline use and these symptoms has not been established.

Nicotine metabolism inhibitors In addition to targeting nAChRs, another approach is to elevate blood nicotine concentrations by reducing nicotine metabolism, thereby decreasing the number of cigarettes smoked. In humans, approximately 80% of absorbed nicotine is metabolized to cotinine by the hepatic enzyme CYP2A6. Nicotine is also excreted unchanged and metabolized to other minor metabolites, but these pathways account for only a small portion of nicotine. Based on this, it has been proposed that CYP2A6 inhibitors may have therapeutic potential for the treatment of tobacco dependence. In support of this hypothesis, it was reported that the strong CYP2A6 inhibitors methoxsalen and tranylcypromine significantly elevate plasma nicotine levels during smoking or NRT treatment and significantly decrease the desire to smoke. Similarly, human subjects with genetically low CYP2A6 activity have an increased likelihood (1.75 fold) of quitting smoking, suggesting that CYP2A6 inhibitors may hold some promise for smoking cessation.

Selegiline Compared to other CYP2A6 inhibitors, selegiline is not only a competitive CYP2A6 inhibitor, but also a selective and irreversible monoamine oxidase B (MAO-B) inhibitor. In the brain, MAO-B is the major enzyme that, together with MAO-A, metabolizes brain DA. Since MAO-B activity is 40% lower in the brain of smokers compared to nonsmokers, and this decrease in MAO-B is reversed during long-term smoking abstinence, it has been suggested that a tobacco smoke component with MAO-B inhibition activity may contribute to the rewarding effects of cigarette smoking. Based on this, selegiline has been investigated as a potential therapy for smoking cessation. Several clinical studies suggest that selegiline is effective in reducing withdrawal symptoms and increasing abstinence compared with placebo. For instance, selegiline has been shown to significantly reduce smoking satisfaction during smoking and decrease craving during abstinence. In addition, it has also been reported that oral selegiline increases smoking cessation trial endpoint (8-week) abstinence compared with placebo by 3-fold. When combined with nicotine patch, selegiline doubled the 52-week continuous abstinence rate compared with nicotine patch alone. In addition, there is no evidence indicating that selegiline is addictive. Taken together, selegiline may have therapeutic potential for smoking cessation by inhibiting both nicotine and DA metabolism.

Nicotine vaccines The nicotine vaccine is a newer strategy being investigated for smoking cessation. The principle of this strategy is to prevent nicotine from entering the brain. In immunized individuals, nicotine obtained from smoking is bound by nicotine-specific antibodies and cannot cross the blood-brain barrier, thus preventing its central effects. Since nicotine itself is not immunogenic, it must be conjugated to larger carrier proteins that can act as immunogenic molecules. Currently, there are at least five companies developing nicotine vaccines using different antigenic molecular approaches. An advantage of nicotine vaccines is that daily administration of the drug is not required, and only occasional booster shots are needed to maintain an adequate antibody titer. A major concern with nicotine vaccines is that the titer of antibodies after immunization may not be sufficient to sequester all of the nicotine in blood, limiting vaccine utility for preventing nicotine entry into the brain during smoking.

Preclinical studies indicate that passive immunization in rats with nicotine antibodies prevents nicotine-conditioned place preference and attenuates withdrawal symptoms. Active immunization with nicotine vaccines significantly reduces (~65%) nicotine distribution into the brain, and inhibits nicotine self-administration, although it failed to
In addition, active immunization also significantly prevents nicotine-triggered reinstatement of nicotine-seeking behavior\(^{99}\). Small-size clinical trials indicate that high doses of nicotine vaccine significantly increase continuous abstinence rates compared with placebo (38% vs 10% for 30 days), and do not cause compensatory smoking behaviors or precipitate withdrawal\(^{100}\). There are two nicotine vaccines, developed by Cytos Biotechnology (http://www.cytos.com) and Nabi Biopharmaceuticals (NicVAXTM) (http://www.nabi.com), which are currently under Phase II clinical trials for smoking cessation. High abstinence rates were achieved with nicotine vaccines compared with the placebo (57% versus 31% at 6 months; 42% versus 21% at 12 months). So far, there have been no serious adverse events associated with such vaccines\(^{80,100}\). These data suggest that nicotine vaccines may be useful for smoking cessation treatment.

**DA-based medication development** As noted above, the mesolimbic DA system is critically involved in drug reward and addiction, including addiction to nicotine\(^{101,102}\). Based on this, much work on the development of new medications for treatment of tobacco addiction has focused on manipulation of DA transmission in the reward circuitry of the brain. Two major pharmacological strategies of manipulating brain DA transmission have emerged as the basis for anti-nicotine medication development: one being to target brain DA receptors with either partial agonists or antagonists, and another being to target brain DA transporters. Although both DA D\(_1\) and D\(_2\) receptors have been shown to be critically involved in drug reward and addiction\(^{103,104}\), clinical trials with D\(_1\)- or D\(_2\)-like receptor antagonists have failed, due to lack of therapeutic effect with D\(_1\)-like agonists or severe side-effects with D\(_2\)-like agonists – such as dysphoria, suppression of natural reward or abnormal movements\(^{105}\). In marked contrast to DA D\(_1\) and D\(_2\) receptors, the D\(_3\) receptor subtype has a restricted distribution in the brain; that is, D\(_3\) receptors are selectively expressed in the mesolimbic DA system with the highest receptor densities in the NAc, islands of Calleja and olfactory tubercle\(^{106,107}\). This restricted neuroanatomic localization suggests that D\(_3\) receptors may play an important role in drug reward and addiction\(^{108}\). In addition, D\(_3\) receptors have the highest affinity for endogenous DA of all known receptors\(^{109,110}\), suggesting a crucial role for D\(_3\) receptors in the normal functioning of the mesolimbic DA system. Moreover, chronic exposure to nicotine significantly increases the expression of D\(_3\) receptor binding and mRNA levels in the mesolimbic DA system\(^{111}\). Based on this, it has been hypothesized that selective D\(_3\) receptor partial agonists or antagonists would be effective in the treatment of nicotine dependence\(^{108,109,112}\).

**DA D\(_3\) receptor partial agonists or antagonists** The rationale for D\(_3\) partial agonists as novel treatments for tobacco dependence is that: 1) D\(_3\) partial agonists are expected to modestly activate D\(_3\) receptors, and therefore blunt cigarette craving and withdrawal during abstinence; and 2) D\(_3\) partial agonists would have additional therapeutic anti-nicotine benefit by blocking nicotine-enhanced DA binding to D\(_3\) receptors. In other words, such a compound can act either as an agonist or antagonist depending on the prevailing DA tone.

**BP-897**BP-897 is the first developed D\(_3\)-selective partial agonist\(^{113}\). It has modest (60–70 fold) selectivity for human D\(_3\) versus D\(_2\) receptors, and similar (60–70 fold) selectivity over other receptors including \(\alpha_1\)-, \(\alpha_2\)-adrenergic, and 5-HT\(_{1A}\) receptors\(^{113}\). In experimental animals, BP-897 produces a significant dose-dependent reduction in the expression of nicotine-induced CPP\(^{111}\), nicotine-enhanced brain stimulation reward (Xi and Gardner, unpublished data), nicotine-conditioned locomotor responses, and nicotine-induced increases in D\(_3\) receptor expression in the NAc\(^{111,114}\). In contrast, BP-897 failed to alter the dose-response curve for nicotine drug discrimination. When substituted for the training dose of nicotine, BP-897 did not produce nicotine-like discriminative-stimulus effects\(^{111}\). In addition, BP-897 fails to alter locomotor activity and food-maintained behavior\(^{115}\). These findings suggest that BP-897 may selectively reduce the motivational effects of nicotine without significant unwanted side-effects by itself. However, enthusiasm for BP-897 has waned due to recent findings that BP-897 also displays full antagonist properties at both DA D\(_3\) and D\(_3\) receptors\(^{116–118}\), suggesting that its therapeutic anti-nicotine effects could be mediated by blockade of D\(_3\) and/or D\(_3\) receptors. Since D\(_3\) receptor antagonism usually produces severe unwanted side-effects, such as dysphoria, inhibition of natural reward, and abnormal extra-pyramidal movements\(^{103–105}\), it is suggested that BP-897, at high doses, may also produce such side-effects at the human level. BP-897 has recently entered Phase II clinical studies, but detailed pharmacokinetic and toxicological data have not yet been reported.

**SB-277011A** SB-277011A is the most well characterized full D\(_3\) receptor antagonist to date. SB-277011A has high affinity for the human cloned DA D\(_3\) receptor, and the ratio of in vitro D\(_3\)/D\(_2\) affinity of SB-277011A for human and rat is 120 and 80, respectively\(^{119}\). SB-277011A has a 100-fold or better selectivity over 180 other receptors, enzymes and ion channels\(^{119}\). A series of studies has assessed the efficacy of SB-277011A in animal models of nicotine dependence\(^{120,121}\). SB-277011A significantly inhibits
nicotine self-administration under progressive-ratio (PR), but not low FR reinforcement schedules\textsuperscript{[122, 123]}, nicotine-induced CPP\textsuperscript{[7]}, nicotine-enhanced brain reward, and nicotine-paired environmental cue functions\textsuperscript{[7]}. In addition, SB-277011A also inhibits nicotine-induced reinstatement of drug-seeking behaviors\textsuperscript{[122]} and nicotine cue-induced conditioned locomotor activity\textsuperscript{[7, 114]}. However, further development of SB-277011A has been halted by Glaxo-SmithKline Pharmaceuticals, due to unexpectedly poor bioavailability (~2\%) and a very short half-life (<20 min) in primates\textsuperscript{[124]}. Therefore, development of other D\textsubscript{1}-selective antagonists with higher bioavailability and more promising pharmacotherapeutic profiles is required\textsuperscript{[125]}. There are two novel DA D3 receptor-selective antagonists, GSK598809, and GSK618334, which are currently under clinical phase I for the treatment of drug addiction, including nicotine dependence (http://clinicaltrials.gov/ct2/results?term=GSK-618334).

**DA transporter (DAT) inhibitors** Although there is no evidence that nicotine can act directly on the DAT protein, several studies suggest a potential relationship\textsuperscript{[126]}. First, a single dose of nicotine enhances DA clearance in rat NAc, suggesting that nicotine regulates extracellular DA concentration via the DAT\textsuperscript{[127]}; and second, nAChR activation by acute and chronic nicotine augments amphetamine-induced reverse transport of DA by the DAT\textsuperscript{[128, 129]}. This DA enhancement by nicotine was fully reversed by the nicotinic receptor antagonists DHβE and mecamylamine, suggesting that nAChRs modulate DAT function\textsuperscript{[128]}. Bupropion Bupropion is an efficacious antidepressant and smoking cessation agent which inhibits the DAT and the norepinephrine transporter in addition to acting as a nicotinic antagonist at α\textsubscript{3}β\textsubscript{2} and α\textsubscript{3}β\textsubscript{4} nAChRs in rat striatum and hippocampus\textsuperscript{[130]}. Bupropion is endorsed by the US Clinical Practice Guideline as a first-line pharmacotherapy for treatment of tobacco abstinence\textsuperscript{[56]}. Since tobacco smokers undergoing cessation often experience symptoms of depression\textsuperscript{[130, 131]}, it is speculated that bupropion's pharmacotherapeutic efficacy may be mediated by its antidepressant effects combined with blockade of the DAT and some nAChRs. In animal studies, acute administration of bupropion attenuated both nicotine-enhanced brain-stimulation reward and the brain-stimulation inhibition associated with nicotine withdrawal\textsuperscript{[132]}. Also, bupropion blocks the acquisition of nicotine-induced CPP and mecamylamine-precipitated withdrawal\textsuperscript{[133]}. In the self-administration paradigm, bupropion produces a biphasic effect: low dose bupropion increases, whereas high dose bupropion decreases, nicotine self-administration in rats\textsuperscript{[134]}. The increase in nicotine self-administration could be a compensatory response to a reduction in nicotine reward after low doses of bupropion. In humans, the majority of studies have demonstrated that bupropion is more effective at improving smoking cessation than placebo\textsuperscript{[135, 136]}. Bupropion has also been reported to reduce nicotine abstinence-associated depression, difficulty concentrating, and irritability, relative to placebo\textsuperscript{[137]}. A recent meta-analysis of several trials shows that bupropion nearly doubles smoking cessation rates with a similar efficacy to NRT\textsuperscript{[138, 139]}.

**Glutamate-based medication development** Glutamate is the major excitatory neurotransmitter in the brain and plays a critical role in the acute and long-term effects of nicotine. The actions of glutamate are mediated by both ionotropic (iGluR) and metabotropic (mGluR) glutamate receptors. The iGluRs include N-methyl-D-aspartate (NMDA), α-amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA) and kainate receptors, which are located primarily on postsynaptic cells and regulate cellular excitability by opening glutamate-gated ion channels. The mGluRs are classified into three groups based on sequence homology, signal transduction pathways and pharmacological actions. Group I (mGluR1 and mGluR5) receptors are predominately located postsynaptically where they couple to G\textsubscript{i/o}-proteins to activate phospholipase C. Group II (mGluR2 and mGluR3) and Group III (mGluR4, mGluR6, mGluR7 and mGluR8) receptors are primarily found presynaptically and on glial cells, and couple to G\textsubscript{i/o} proteins to negatively regulate adenylyl cyclase activity. Activation of group II or III mGluRs negatively modulates glutamate release.

Nicotine binds with high affinity to nAChRs located on presynaptic glutamatergic terminals in various brain sites, including the VTA, NAc, prefrontal cortex and hippocampus, producing an increase in glutamate release\textsuperscript{[32, 140, 141]}. In the VTA, the α7 nAChR subtype has been shown to be localized on VTA DA neurons\textsuperscript{[31, 32]} and presynaptic glutamatergic afferents\textsuperscript{[142]}. Activation of the α7 receptors by nicotine increases glutamate release in the VTA and activates iGluRs located postsynaptically on VTA DA neurons (Figure 1), with the end result being an increase in the activity of the mesolimbic reward circuit\textsuperscript{[139, 141]}. Behaviorally, repeated administration of nicotine causes a long-lasting motor sensitization\textsuperscript{[143, 144]} that has been suggested to play a role in nicotine’s addictive properties\textsuperscript{[145]}. Glutamatergic and dopaminergic mechanisms within the VTA and NAc have been implicated in this nicotine sensitization\textsuperscript{[145]}. Pharmacological studies on nicotine reinforcement, relapse, and withdrawal have provided important information regarding possible glutamate-based interventions for the treatment of nicotine addiction\textsuperscript{[141]}. The effects of glutamate compounds on nico-
tine dependence are likely to be mediated by attenuation of nicotine-stimulated glutamate transmission in the mesolimbic system via blockade of either presynaptic mGluR2/3 receptors or postsynaptic mGluR5 or NMDA receptors.

**mGluR2/3 receptor agonists** Considering that mGluR2/3 are located presynaptically and negatively modulate glutamate release, it has been proposed that activation of mGluR2/3 receptors by agonists would decrease presynaptic glutamate release, and therefore block the rewarding effects of nicotine and cigarette smoking.

**LY379268** LY379268 is a potent, systemically active mGluR2/3 agonist. Systemic or local administration of LY379268 into the posterior VTA or the NAc shell dose dependently inhibits nicotine self-administration at doses that have no effect on food-taking behavior. LY379268 also reverses cue-induced reinstatement of both nicotine- and food-seeking behaviors. In addition, LY379268 attenuates reward deficits associated with spontaneous nicotine withdrawal in rats. However, when LY379268 is given alone, it inhibits brain-stimulation reward in rats. These data suggest that LY379268 or other mGluR2/3 agonists may have some utility for the treatment of nicotine withdrawal and dependence. However, LY379268, at doses that inhibited cue-induced reinstatement of nicotine seeking, also inhibited food seeking, suggesting that stimulatory actions at presynaptic inhibitory mGluR2/3 have general effects on the motivational impact of conditioned reinforcers. In addition, rapid tolerance occurred to the LY379268-induced decreases in nicotine self-administration, which may also limit the potential use of this compound for the treatment of nicotine dependence.

**mGluR5 receptor antagonists** The mGluR5 receptor has become an important target in medication discovery for treatment of addiction, largely because of its relatively selective regional distribution in the brain and predominantly postsynaptic location. mGluR5 blockade has been proposed to attenuate nicotine-enhanced glutamate transmission in the mesolimbic DA system, and therefore attenuating the rewarding effects of nicotine. A large body of literature indicates that mGluR5s play an important role in behavioral responses to nicotine.

**MPEP** 2-methyl-6-(phenylethynyl)-pyridine (MPEP) is a selective mGluR5 antagonist. It has been shown to decrease nicotine self-administration in mice and rats. MPEP also decreases progressive-ratio reinforcement breaking points for nicotine self-administration more than break points for food-taking behavior. MPEP also reduces reinstatement of nicotine-seeking behavior induced by a nicotine priming injection or by re-exposure to environmental cues previously associated with nicotine self-administration, but not by cues associated with food-taking behavior. However, MPEP does not block the ability of nicotine to enhance brain-reward, nor does it block the development of nicotine-induced CPP. Thus, although MPEP may be of some clinical benefit in reducing cigarette smoking or relapse during attempts to quit, it may not significantly attenuate the effects of nicotine on brain reward functions. In addition to MPEP, it was recently reported that MTEP (3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]-pyridine), a novel highly selective mGluR5 antagonist, also significantly inhibits nicotine seeking, but does not affect the reinforcement enhancing effects of nicotine.

**NMDA receptor antagonists** NMDA receptor blockade either globally via systemic administration of an NMDA receptor antagonist or locally via injections of an NMDA receptor antagonist directly into the VTA or the central nucleus of the amygdala decreases intravenous nicotine self-administration in rats. The effects of NMDA receptor antagonists on intravenous nicotine self-administration occur at doses that do not effect responding for food reinforcement under similar schedules of reinforcement.

**Memantine** Memantine is a non-competitive, selective NMDA receptor antagonist, and is clinically used for the treatment of dementia. The efficacy of memantine for the treatment of nicotine addiction has been investigated as well. In a preclinical study, memantine was found to block the acquisition of nicotine self-administration. However, in humans, memantine does not influence cigarette consumption, craving, or estimation of nicotine's hedonic effects under conditions of instructed smoking reduction, nor does it significantly disturb sensory components of learning mechanisms relevant for the acquisition and maintenance of nicotine dependence.

**GABA-based medication development** GABA is the most important inhibitory neurotransmitter in the mammalian CNS and it has been shown to play an important role in mediating the reinforcing effects of nicotine. GABAergic afferents to the VTA originate from the pedunculopontine tegmental nucleus, ventral pallidum and NAc. Also, GABAergic interneurons within the VTA exert inhibitory control over VTA DA neurons. The central effects of GABA are mediated by both ionotropic GABA A and metabotropic GABA B receptors. GABA A receptors are located predominantly on postsynaptic cells and functionally lower their excitability. In contrast, GABA B receptors are predominantly located on presynaptic terminals, and inhibit presynaptic neurotransmitter release. Consequently, any pharmacological strategy that increases GABAergic trans-
mission within brain reward circuits by either elevating extracellular GABA levels or directly activating GABA receptors would inhibit nicotine-induced increases in NAc DA and subsequent nicotine reinforcement\[^{132}\].

**Gamma-vinyl GABA (GVG, vigabatrin)** GVG is an irreversible inhibitor of GABA transaminase, the primary enzyme involved in GABA metabolism\[^{162}\]. GABA transaminase is essential for GABA's metabolic breakdown, and therefore its inhibition elevates brain GABA levels. GVG has been shown to dose-dependently attenuate nicotine-induced increases in extracellular DA in the NAc\[^{163}\]. GVG also decreases nicotine self-administration\[^{164}\] and abolishes both the acquisition and the expression of nicotine-conditioned place preference\[^{165}\]. In addition, GVG dose-dependently lowers nicotine-induced increases in NAC DA in both naive and chronically nicotine-treated rats, and blocks nicotine-induced increases in striatal DA in non-human primates as measured by positron emission tomography\[^{166}\]. These results suggest that GVG may have potential utility as an antinicotine therapeutic medication. GVG is currently in Phase II clinical trials for cocaine dependence, but not for nicotine dependence.

**Baclofen** Baclofen is a systemically active GABA\(_{B}\) receptor agonist. It has been reported that baclofen dose-dependently inhibits nicotine-induced increases in NAC DA release\[^{167}\]. Systemic injections or microinjections of baclofen into the VTA, NAc shell, or pedunculopontine tegmental nucleus (that sends cholinergic, GABAergic and glutamatergic projections to the VTA) inhibits nicotine self-administration in rats and mice\[^{35, 168–171}\]. In addition, baclofen, at high doses, completely inhibits nicotine-induced CPP and food-reinforced responding, but fails to reduce nicotine’s drug discriminative effects\[^{49}\]. A small-scale clinical study (16 patients) indicated that a single dose of baclofen (20 mg/kg) significantly altered the sensory properties of smoked cigarettes (eg, increasing ratings of 'harsh' and decreasing ratings of 'like cigarette's effects), produced mild sedative-like effects, but failed to reduce cigarette craving or the number of cigarettes smoked\[^{172}\]. Large-scale clinical trials with multiple drug treatment regimens are required for fully evaluating baclofen's efficacy in the treatment of nicotine dependence. On a cautionary note, baclofen may have undesired side-effects, as indicated by preclinical findings that high dose baclofen significantly inhibited locomotor activity and rotarod locomotor performance\[^{49, 173}\], and decreased responding for non-drug rewards, such as food and electrical brain stimulation reward\[^{164, 171, 174}\].

GS39783 and BSF177 GS39783 and BSF177 are novel GABA\(_{B}\) receptor-positive allosteric modulators\[^{175, 176}\]. Since positive allosteric modulators bind to a site distinct from the agonist binding pocket, they do not alter or perturb receptor signaling on their own, but potentiate the effect of GABA when endogenous GABA is released. Recent studies demonstrate that such positive allosteric compounds significantly inhibits nicotine self-administration under both FR and PR reinforcement schedules and attenuates nicotine-induced CPP and nicotine-enhanced brain-stimulation reward\[^{177, 178}\]. Strikingly, these effects were seen at a range of doses that neither altered food-taking behavior nor impaired rotarod locomotor performance in rats\[^{173, 178}\]. These findings suggest that GABA\(_{B}\) receptor positive allosteric modulators may have similar pharmacotherapeutic effects for smoking cessation as the full GABA\(_{B}\) receptor agonist baclofen, but with fewer side-effects.

**Endocannabinoid-based medication development** Recent studies suggest that the endocannabinoid system also plays an important role in nicotine's addictive properties\[^{179, 180}\]. This is supported by evidence that: 1) co-administration of sub-threshold doses of a cannabinoid agonist and nicotine produces an enhanced rewarding effect\[^{181}\]; 2) chronic administration of nicotine in rats produces increases in endocannabinoid (anandamide) levels in the limbic forebrain and in both anandamide and 2-arachidonoyl-glycerol in the brainstem, although CB\(_1\) receptor binding and CB1 mRNA levels were not affected\[^{182}\]; 3) the rewarding effects of nicotine, assessed in the CPP paradigm, are absent in CB1 receptor knockout mice\[^{183}\], though the absence of CB1 receptors does not modify the acquisition of nicotine self-administration\[^{184}\]; and 4) endocannabinoid agonists have been shown to facilitate DA neuron activity in the VTA and increase DA release in the NAC\[^{185}\], whereas cannabinoid CB1 receptor antagonists inhibit nicotine self-administration and nicotine-seeking behavior\[^{181, 186}\]. It is generally believed that such cannabinoid effects are mediated by activation of CB1 receptors located on presynaptic GABAergic neurons in the VTA and/or the NAc, causing a decrease in GABA release and an increase in NAc DA release\[^{181}\]. Based on this, CB1 receptor antagonists may have utility for smoking cessation.

**SR141716A (Rimonabant)** SR141716A is the first developed CB1 receptor antagonist\[^{187}\], and has become an important tool for research on cannabinoid involvement in nicotine's addictive properties. In preclinical studies, rimonabant dose-dependently blocks the nicotine-induced elevations in NAc DA and attenuates nicotine self-administration\[^{188}\]. Rimonabant also attenuates the expression and development of nicotine-induced CPP\[^{189, 190}\] and blocks environmental cue-induced reinstatement of nicotine-seeking\[^{180, 181}\].
humans, one trial gave both rimonabant and a nicotine patch or rimonabant and a placebo patch to smokers who were motivated to quit. The rimonabant and nicotine patch produced abstinence rates of 39% during weeks 6–9 of treatment, compared with 21.3% of patients treated with rimonabant and placebo. However, it has been recently reported that rimonabant increases anxiety and depressive symptoms. Because of these potential adverse effects, the US FDA has not currently approved its use in humans.

AM251 AM251 is a novel CB1 antagonist, structurally similar to rimonabant. AM251 reverses locomotor sensitization to a nicotine challenge and nicotine-induced elevations in extracellular serotonin in the rat hippocampus. AM251 also dose-dependently suppresses intravenous nicotine self-administration in rats. The self-administration behavior was reinstated by suspending AM251 treatment. Also, pretreatment with AM251 dose-dependently attenuates nicotine-induced and nicotine-associated cue-induced relapse to nicotine-seeking behavior. AM251 has not yet been evaluated clinically.

Conclusion

Given the prevalence and serious consequences of smoking and nicotine dependence, the development of effective therapies to aid smoking cessation is imperative. In this article, we have reviewed the neurochemical bases underlying the pharmacological actions of nicotine and nicotine reinforcement, and evaluated the pharmacological actions of a number of promising agents that target brain substrates on which nicotine acts in both preclinical and clinical models. Though these compounds are different pharmacologically and mechanistically, they all work by interfering with nicotine’s actions in the mesolimbic DA reward and relapse system. Recent success with some of these compounds, such as varenicline and bupropion, highlights the importance of preclinical medication development with animal models of drug dependence. These mechanism-based pharmacological strategies may lead to more novel compounds for evaluation in human trials for smoking cessation. If any one demonstrates significant anti-nicotine reward, anti-nicotine craving and anti-relapse efficacy in humans, the beneficial impact on addiction medicine will be considerable.

Acknowledgements

This research was supported by the Intramural Research Program of the National Institute on Drug Abuse, National Institutes of Health.

References

1. Centers for Disease Control and Prevention C. Cigarette smoking among adults- United States, 2006. In Morbidity and Mortality Weekly Report. 2007; serial online.
2. Who Report on the Global Tobacco Epidemic. The MPOWER Package. Geneva, World Health Organization, 2008. www.who.int/tobacco/mpower/mpower_report.
3. Goldberg SR, Spealman RD, Goldberg DM. Persistent behavior at high rates maintained by intravenous self-administration of nicotine. Science 1981; 214: 573–5.
4. Watkins SS, Koob GF, Markou A. Neural mechanisms underlying nicotine addiction: acute positive reinforcement and withdrawal. Nicotine Tob Res 2000; 2: 19–37.
5. Clarke PB, Kumar R. The effects of nicotine on locomotor activity in non-tolerant and tolerant rats. Br J Pharmacol 1983; 78: 329–37.
6. Clarke PB. Dopaminergic mechanisms in the locomotor stimulant effects of nicotine. Biochem Pharmacol 1990; 40: 1427–32.
7. Pak AC, Ashby CR Jr, Heidbreder CA, Pilla M, Gilbert J, Xi ZX, et al. The selective dopamine D3 receptor antagonist SB-277011A reduces nicotine-enhanced brain reward and nicotine-paired environmental cue functions. Int J Neuropsychopharmacol 2006; 9: 585–602.
8. Corrigall WA. Nicotine self-administration in animals as a dependence model. Nicotine Tob Res 1999; 1: 11–20.
9. Di Chiara G. Role of dopamine in the behavioural actions of nicotine related to addiction. Eur J Pharmacol 2000; 393: 295–314.
10. Rosecrans JA, Villanueva HF. Discriminative stimulus properties of nicotine: mechanisms of transduction. NIDA Res Monogr 1991; (116): 101–16.
11. Epping-Jordan MP, Watkins SS, Koob GF, Markou A. Dramatic decreases in brain reward function during nicotine withdrawal. Nature 1998; 393: 76–9.
12. Dani JA, De Biasi M. Cellular mechanisms of nicotine addiction. Pharmacol Biochem Behav 2001; 70: 439–46.
13. Jones S, Sudweeks S, Yakel JL. Nicotinic receptors in the brain: correlating physiology with function. Trends Neurosci 1999; 22: 555–61.
14. Le Novere N CP, Changeux,JP. The diversity of subunit composition in nAChRs: evolutionary origins, physiologic and pharmacologic consequences. J Neurobiol 2002; 53: 447–56.
15. McGehee DS, Role LW. Physiological diversity of nicotinic acetylcholine receptors expressed by vertebrate neurons. Annu Rev Physiol 1995; 57: 521–46.
16. Wonnacott S. Presynaptic nicotinic ACh receptors. Trends Neurosci 1997; 20: 92–8.
17. Buchalter AR, Fant RV, Henningfield JE. Novel pharmacological approaches for treating tobacco dependence and withdrawal: current status. Drugs 2008; 68: 1067–88.
18. Wise RA. Dopamine, learning and motivation. Nat Rev Neurosci 2004; 5: 483–94.
19. Dani JA, Heinemann S. Molecular and cellular aspects of nicotine abuse. Neuron 1996; 16: 905–8.
20. Corrigall WA, Coen KM, Adamson KL. Self-administered nicotine activates the mesolimbic dopamine system through the ventral tegmental area. Brain Res 1994; 653: 278–84.
21 Corrigall WA, Franklin KB, Coen KM, Clarke PB. The mesolimbic dopaminergic system is implicated in the reinforcing effects of nicotine. Psychopharmacology (Berl) 1992; 107: 285–9.
22 Watkins SS, Epping-Jordan MP, Koob GF, Markou A. Blockade of nicotine self-administration with nicotinic antagonists in rats. Pharmacol Biochem Behav 1999; 62: 743–51.
23 Cohen C, Bergis OE, Galli F, Locheid AW, Jegham S, Biton B, Watkins SS, Epping-Jordan MP, Koob GF, Markou A. Blockade of nicotine self-administration with nicotinic antagonists in rats. Pharmacol Biochem Behav 1999; 62: 743–51.
24 Picciotto MR, Zoli M, Rimondini R, Lena C, Marubio LM, Pich EM, et al. Acetylcholine receptors containing the beta2 subunit are involved in the reinforcing properties of nicotine. Nature 1998; 391: 173–7.
25 Marubio LM, Gardier AM, Durier S, David D, Klink R, Arroyo-Jimenez MM, et al. Effects of nicotine in the dopaminergic system of mice lacking the alpha4 subunit of neuronal nicotinic acetylcholine receptors. Eur J Neurosci 2003; 17: 1329–37.
26 Pidoplichko VI, DeBiasi M, Williams JT, Dani JA. Nicotine activates and desensitizes midbrain dopamine neurons. Nature 1997; 390: 401–4.
27 Klink R, de Kerchove d’Exaerde A, Zoli M, Changeux JP. Molecular and physiological diversity of nicotinic acetylcholine receptors in the midbrain dopaminergic nuclei. J Neurosci 2001; 21: 1452–63.
28 Wooltorton JR, Pidoplichko VI, Broide RS, Dani JA. Differential desensitization and distribution of nicotinic acetylcholine receptor subtypes in midbrain dopamine areas. J Neurosci 2003; 23: 3176–85.
29 Picciotto MR, Zoli M, Lena C, Bessis A, Lallemand Y, Le Novere N, et al. Abnormal avoidance learning in mice lacking functional high-affinity nicotine receptor in the brain. Nature 1995; 374: 65–7.
30 Mansvelder HD, McGeehe DS. Cellular and synaptic mechanisms of nicotine addiction. J Neurobiol 2002; 53:606–17.
31 Wu J, George AA, Schroeder KM, Xu L, Marker-Miller S, Lucero L, et al. Electrophysiological, pharmacological, and molecular evidence for alpha7-nicotinic acetylcholine receptors in rat midbrain dopamine neurons. J Pharmacol Exp Ther 2004; 311: 80–91.
32 Yang K, Hu J, Lucero L, Liu Q, Zheng C, Zhen X, et al. Distinctive nicotinic acetylcholine receptor functional phenotypes of rat ventral tegmental area dopaminergic neurons. J Physiol 2009; 587 (Pt 2): 345–61.
33 Azam L, Winzer-Serhan UH, Chen Y, Leslie FM. Expression of neuronal nicotinic acetylcholine receptor subunit mRNAs within midbrain dopamine neurons. J Comp Neurol 2002; 444: 260–74.
34 Mansvelder HD, McGeehe DS. Long-term potentiation of excitatory inputs to brain reward areas by nicotine. Neuron 2000; 27: 349–57.
35 Corrigall WA, Coen KM, Adamson KL, Chow BL, Zhang J. Response of nicotine self-administration in the rat to manipulations of mu-opioid and gamma-aminobutyric acid receptors in the ventral tegmental area. Psychopharmacology (Berl) 2000; 149: 107–14.
36 Markou A. Review. Neurobiology of nicotine dependence. Philos Trans R Soc Lond B Biol Sci 2008; 363: 3159–68.
37 Markou A, Paterson NE. The nicotinic antagonist methyllycaconitine has differential effects on nicotine self-administration and nicotine withdrawal in the rat. Nicotine Tob Res 2001; 3: 361–73.
38 Besson M, Granon S, Mameli-Engvall M, Cloez-Tayarani I, Maubourguet N, Cormier A, et al. Long-term effects of chronic nicotine exposure on brain nicotinic receptors. Proc Natl Acad Sci U S A 2007; 104: 8155–60.
39 Russell MA. Subjective and behavioural effects of nicotine in humans: some sources of individual variation. Prog Brain Res 1989; 79: 289–302.
40 Peng X, Gerzanich V, Anand R, Whiting PJ, Lindstrom J. Nicotine-induced increase in neuronal nicotinic receptors results from a decrease in the rate of receptor turnover. Mol Pharmacol 1994; 46: 523–30.
41 Fenster CP, Hicks JH, Beckman ML, Coverton PJ, Quick MW, Lester RA. Desensitization of nicotinic receptors in the central nervous system. Ann N Y Acad Sci 1999; 868: 620–3.
42 Buisson B, Bertrand D. Chronic exposure to nicotine upregulates the human (alpha)4((beta)2 nicotinic acetylcholine receptor function. J Neurosci 2001; 21: 1819–29.
43 Grottick AJ, Wyler R, Higgins GA. The alpha4beta2 agonist SIB 176SF, but not the alpha7 agonist AR-R 17779, cross-sensitises to the psychostimulant effects of nicotine. Psychopharmacology (Berl) 2000; 150: 233–6.
44 Shoai M, Stolerian IP. Locomotor activity after nicotine infusions into the fourth ventricle of rats. Pharmaco Biochem Behav 1994; 48:749–54.
45 Shoai M, Schindler CW, Goldberg SR. Nicotine self-administration in rats: strain and nicotine pre-exposure effects on acquisition. Psychopharmacology (Berl) 1997; 129: 35–43.
46 O’Brien CP, Gardner EL. Critical assessment of how to study addiction and its treatment: human and non-human animal models. Pharmacol Ther 2005; 108: 18–58.
47 Richardson NR, Roberts DC. Progressive ratio schedules in drug self-administration studies in rats: a method to evaluate reinforcing efficacy. J Neurosci Methods 1996; 66: 1–11.
48 Shalev U, Grimm JW, Shaham Y. Neurobiology of relapse to heroin and cocaine seeking: a review. Pharmacol Rev 2002; 54: 1–42.
49 Le Foll B, Wertheim CE, Goldberg SR. Effects of baclofen on conditioned rewarding and discriminative stimulus effects of nicotine in rats. Neurosci Lett 2008; 443: 236–40.
50 Wise RA. Neurobiology of addiction. Curr Opin Neurobiol 1996; 6: 243–51.
51 Malin DH, Lake JR, Carter VA, Cunningham JS, Hebert KM, Conrad DL, et al. The nicotinic antagonist mecamylamine precipitates nicotine abstinence syndrome in the rat. Psychopharmacology (Berl) 1994; 115: 180–4.
52 Grabus SD, Martin BR, Batman AM, Tyndale RF, Sellers E, Damaj MI. Nicotine physical dependence and tolerance in the mouse following chronic oral administration. Psychopharmacology (Berl) 2005; 178: 183–92.
53 Malin DH. Nicotine dependence: studies with a laboratory model. Pharmacol Biochem Behav 2001; 70: 551–9.
54 Hildebrand BE, Nomikos GG, Hertel P, Schilstrom B, Svensson TH. Reduced dopamine output in the nucleus accumbens but not in the medial prefrontal cortex in rats displaying a mecamylamine-
precipitated nicotine withdrawal syndrome. Brain Res 1998; 779: 214–25.
55 Kenny PJ, Markou A. Neurobiology of the nicotine withdrawal syndrome. Pharmacol Biochem Behav 2001; 70: 531–49.
56 Fiore MC. Treating tobacco use and dependence: an introduction to the US Public Health Service Clinical Practice Guideline. Respir Care 2000; 45: 1196–9.
57 Shytte RD, Penny E, Silver AA, Goldman J, Sanberg PR. Mecamylamine (Inversine): an old antihypertensive with new research directions. J Hum Hypertens 2002; 16: 453–7.
58 Rose JE, Behm FM, Westman EC. Nicotine-mecamylamine treatment for smoking cessation: the role of pre-cessation therapy. Exp Clin Psychopharmacol 1998; 6: 331–43.
59 Rose JE, Behm FM, Westman EC, Levin ED, Stein RM, Ripka GV. Mecamylamine combined with nicotine skin patch facilitates smoking cessation beyond nicotine patch treatment alone. Clin Pharmacol Ther 1994; 56: 86–99.
60 Corrigall WA, Coen KM. Nicotine maintains robust self-administration in rats on a limited-access schedule. Psychopharmacology (Berl) 1989; 99: 473–8.
61 Risner ME, Goldberg SR. A comparison of nicotine and cocaine self-administration in the dog: fixed-ratio and progressive-ratio schedules of intravenous drug infusion. J Pharmacol Exp Ther 1983; 224: 319–26.
62 Ivanova S, Greenshaw AJ. Nicotine-induced decreases in VTA electrical self-stimulation thresholds: blockade by haloperidol and mecamylamine but not scopolamine or ondansetron. Psychopharmacology (Berl) 1997; 134: 187–92.
63 Fudala PJ, Teoh KW, Iwamoto ET. Pharmacologic characterization of nicotine-induced conditioned place preference. Pharmacol Biochem Behav 1985; 22: 237–41.
64 Benwell ME, Balfour DJ, Birrell CE. Desensitization of the nicotine-induced mesolimbic dopamine responses during constant infusion with nicotine. Br J Pharmacol 1995; 114: 454–60.
65 Nemeth-Coslett R, Henningfield JE, O’Keefe MK, Griffiths RR. Effects of mecamylamine on human cigarette smoking and subjective ratings. Psychopharmacology (Berl) 1986; 88: 420–5.
66 Glover ED, Laffin MT, Schuh KJ, Schuh LM, Nides M, Christen AG, et al. A randomized, controlled trial to assess the efficacy and safety of a transdermal delivery system of nicotine/mecamylamine in mice is associated with rates of nicotine inactivation by CYP2A6. Psychopharmacology (Berl) 2006; 184: 401–8.
67 Lerman C, Tyndale R, Patterson F, Wileyto EP, Shields PG, Pinto A, et al. Nicotine metabolite ratio predicts efficacy of transdermal nicotine for smoking cessation. Clin Pharmacol Ther 2006; 79: 600–8.
68 Malaiyandi V, Lerman C, Benowitz NL, Jepson C, Patterson F, Tyndale RF. Effect of CYP2A6 genotype on pretreatment smoking behaviour and nicotine levels from and usage of nicotine replacement therapy. Mol Psychiatry 2006; 11: 400–9.
69 Sellers EM, Kaplan HL, Tyndale RF. Inhibition of cytochrome P450 2A6 increases nicotine’s oral bioavailability and decreases smoking. Clin Pharmacol Ther 2000; 68: 35–43.
70 Gu DF, Hinks LJ, Morton NE, Day IN. The use of long PCR to confirm three common alleles at the CYP2A6 locus and the relationship between genotype and smoking habit. Ann Hum Genet 2000; 64: 383–90.
71 Youdim MB, Bakhlle YS. Monoamine oxidase: isoforms and inhibitors in Parkinson’s disease and depressive illness. Br J Pharmacol 2006; 147 Suppl 1: S287–96.
72 Fowler JS, Volkow ND, Wang GJ, Pappas N, Logan J, Shea C, et al. Brain monoamine oxidase A inhibition in cigarette smokers. Proc Natl Acad Sci U S A 1996; 93: 14065–9.
73 Gilbert DG, Zuo Y, Browning RA, Shaw TM, Rabinovich NE, Gilbert-Johnson AM, et al. Platelet monoamine oxidase B activity
changes across 31 days of smoking abstinence. Nicotine Tob Res 2003; 5: 813–9.

90 Khalil AA, Steyn S, Castagnoli NJ Jr. Isolation and characterization of a monoamine oxidase inhibitor from tobacco leaves. Chem Res Toxicol 2000; 13: 31–5.

91 Lewis A, Miller JH, Lea RA. Monoamine oxidase and tobacco dependence. Neurotoxicology 2007; 28: 182–95.

92 Houtsomuller EJ, Thornton JA, Stitzer ML. Effects of selegiline (L-deprenyl) during smoking and short-term abstinence. Psychopharmacology (Berl) 2002; 163: 213–20.

93 George TP, O’Malley SS. Current pharmacological treatments for nicotine dependence. Trends Pharmacol Sci 2004; 25: 42–8.

94 Ribberman R, Neumann R, Katzir I, Gerber Y. A randomized controlled trial of oral selegiline plus nicotine skin patch compared with placebo plus nicotine skin patch for smoking cessation. Addiction 2003; 98: 1403–7.

95 Schneider LS, Tariot PN, Goldstein B. Therapy with L-deprenyl (selegiline) and relation to abuse liability. Clin Pharmacol Ther 1994; 56: 750–6.

96 Malin DH, Lake JR, Lin A, Saldana M, Balch L, Irvin ML, et al. Passive immunization against nicotine prevents nicotine alleviation of nicotine abstinence syndrome. Pharmacol Biochem Behav 2001; 68: 87–92.

97 Hieda Y, Keyler DE, Ennifar S, Fattom A, Pentel PR. Vaccination against nicotine during continued nicotine administration in rats: immunogenicity of the vaccine and effects on nicotine distribution to brain. Int J Immunopharmacol 2000; 22: 809–19.

98 LeSage MG, Keyler DE, Pentel PR. Current status of immunologic approaches to treating tobacco dependence: vaccines and nicotine-specific antibodies. Aaps J 2006; 8: E65–75.

99 Lindblom N, de Villiers SH, Kalayanov G, Gordon S, Johansson AM, Svensson TH. Active immunization against nicotine prevents reinstatement of nicotine-seeking behavior in rats. Respiration 2002; 69: 254–60.

100 Hatsuuki DM, Kotlyar M, Allen S, Jensen J, Li S, Le C, et al. Effects of cigarette reduction on cardiovascular risk factors and subjective measures. Chest 2005; 128: 2528–37.

101 Koob GF, Bloom FE. Cellular and molecular mechanisms of drug dependence. Science 1988; 242: 715–23.

102 Wise RA. Forebrain substrates of reward and motivation. J Comp Neurol 2005; 493: 115–21.

103 Rothman RB, Glowa JR. A review of the effects of dopaminergic agents on humans, animals, and drug-seeking behavior, and its implications for medication development. Focus on GBR 12909. Mol Neurobiol 1995; 11: 1–19.

104 Platt DM, Rowlett JK, Spealman RD. Behavioral effects of cocaine and dopaminergic strategies for preclinical medication development. Psychopharmacology (Berl) 2002; 163: 265–82.

105 Gorelick DA, Gardner EL, Xi ZX. Selective inhibition of cocaine-seeking behavior by a partial dopamine D3 receptor agonist. Nature 1999; 400: 371–5.

106 LeFoll B, Schwartz JC, Sokoloff P. Disruption of nicotine conditioning by dopamine D3(3) receptor ligands. Mol Psychiatry 2003; 8: 225–30.

107 LeFoll B, Frances H, Diaz J, Schwartz JC, Sokoloff P. Role of the dopamine D3 receptor in reactivity to cocaine-associated cues in mice. Eur J Neurosci 2002; 15: 2016–26.

108 Sokoloff P, Diaz J, Le Foll B, Guilain L, Leriche L, Bezd E, et al. The dopamine D3 receptor: a therapeutic target for the treatment of neuropsychiatric disorders. CNS Neurol Disord Drug Targets 2006; 5: 25–43.

109 Sokoloff P, Le Foll B, Perachon S, Bordet R, Ridray S, Schwartz JC. The dopamine D3 receptor and drug addiction. Neurotox Res 2001; 3: 433–41.

110 Levant B. The D3 dopamine receptor: neurobiology and potential clinical relevance. Pharmacol Rev 1997; 49: 231–52.

111 LeFoll B, Sokoloff P, Stark H, Goldberg SR. Dopamine D3 receptor ligands block nicotine-induced conditioned place preferences through a mechanism that does not involve discriminative-stimulus or antidepressant-like effects. Neuropsychopharmacology 2005; 30: 720–30.

112 Caine SB, Koob GF. Modulation of cocaine self-administration in the rat through D3 dopamine receptors. Science 1993; 260: 1814–6.

113 Pilla M, Perachon S, Sautel F, Garrido F, Mann A, Wermuth CG, et al. Selective inhibition of cocaine-seeking behaviour by a partial dopamine D3 receptor agonist. Nature 1999; 400: 371–5.

114 LeFoll B, Schwartz JC, Sokoloff P. Disruption of nicotine conditioning by dopamine D(3) receptor ligands. Mol Psychiatry 2003; 8: 225–30.

115 LeFoll B, Frances H, Diaz J, Schwartz JC, Sokoloff P. Role of the dopamine D3 receptor in reactivity to cocaine-associated cues in mice. Eur J Neurosci 2002; 15: 2016–26.

116 Wood MD, Boyfield I, Nash DJ, Jewitt FR, Avenell KY, Riley GJ. Evidence for antagonist activity of the dopamine D3 receptor partial agonist, BP 897, at human dopamine D3 receptor. Eur J Pharmacol 2000; 407: 47–51.

117 Wicke K, Garcia-Ladona J. The dopamine D3 receptor partial agonist, BP 897, is an antagonist at human dopamine D3 receptors and at rat somatodendritic dopamine D3 receptors. Eur J Pharmacol 2001; 424: 85–90.

118 Heidbreder CA, Gardner EL, Xi ZX, Thanos PK, Mugnaini M, Hagan JJ, et al. The role of central dopamine D3 receptors in drug addiction: a review of pharmacological evidence. Brain Res Brain Res Rev 2005; 49: 77–105.

119 Reavill C, Taylor SG, Wood MD, Ashmeade T, Austin NE, Avenell KY, et al. Pharmacological actions of a novel, high-affinity, and selective human dopamine D(3) receptor antagonist, SB-277011-A. J Pharmacol Exp Ther 2000; 294: 410–21.

120 LeFoll B, Goldberg SR, Sokoloff P. Dopamine D3 receptor ligands for the treatment of tobacco dependence. Expert Opin Investig Drugs 2007; 16: 45–57.

121 Heidbreder C. Selective antagonism at dopamine D3 receptors as a target for drug addiction pharmacotherapy: a review of preclinical evidence. CNS Neurol Disord Drug Targets 2008; 7: 410–21.

122 Andreoli M, Tessari M, Pilla M, Valerio E, Hagan JJ, Heidbreder CA. Selective antagonism at dopamine D3 receptors prevents nicotine-triggered relapse to nicotine-seeking behavior. Neuropsychopharmacology 2003; 28: 1272–80.

123 Ross JT, Corrigall WA, Heidbreder CA, LeSage MG. Effects of the selective dopamine D3 receptor antagonist SB-277011A on the reinforcing effects of nicotine as measured by a progressive-ratio schedule in rats. Eur J Pharmacol 2007; 559: 173–9.
124 Remington G, Kapur S. SB-277011 GlaxoSmithKline. Curr Opin Invest Drugs 2001; 2: 946–9.
125 Newman AH, Grundt P, Nader MA. Dopamine D3 receptor partial agonists and antagonists as potential drug abuse thera-
peutic agents. J Med Chem 2005; 48: 3663–79.
126 Zhu J, Reith ME. Role of the dopamine transporter in the action of psychostimulants, nicotine, and other drugs of abuse. CNS 
Neurol Disord Drug Targets 2008; 7: 393–409.
127 Hart C, Ksir C. Nicotine effects on dopamine clearance in rat 
nucleus accumbens. J Neurochem 1996; 66: 216–21.
128 Drew AE, Derbez AE, Werling LL. Nicotinic receptor-mediated 
regulation of dopamine transporter activity in rat prefrontal 
cortex. Synapse 2000; 38: 10–6.
129 Drew AE, Werling LL. Nicotinic receptor-mediated regulation of 
the dopamine transporter in rat prefrontocortical slices following 
chronic in vivo administration of nicotine. Schizophr Res 2003; 
65: 47–55.
130 Miller DK, Sumithran SP, Dwoskin LP. Bupropion inhibits 
nicotine-evoked [3H]overflow from rat striatal slices preloaded 
with [3H]dopamine and from rat hippocampal slices preloaded with 
[3H]norepinephrine. J Pharmacol Exp Ther 2002; 302: 
1113–22.
131 Covey LS, Glassman AH, Stetner F. Major depression following 
smoking cessation. Am J Psychiatry 1997; 154: 263–5.
132 Cryan JF, Bruijnzeel AW, Skjei KL, Markou A. Bupropion 
enhances brain reward function and reverses the affective 
and somatic aspects of nicotine withdrawal in the rat. Psychopharma-
cology (Berl) 2003; 168: 347–58.
133 Malin DH, Lake JR, Smith TD, Khambiti HN, Meyers-Paal RL, 
Montellano AL, et al. Bupropion attenuates nicotine abstinence 
syndrome in the rat. Psychopharmacology (Berl) 2003; 169: 
1–9.
134 Rauhut AS, Neugebauer N, Dwoskin LP, Bardo MT. Effect of 
bupropion on nicotine self-administration in rats. Psychopharma-
cology (Berl) 2003; 169: 1–9.
135 Hays JT, Dale LC, Hurt RD, Croghan IT. Trends in smoking-
related diseases. Why smoking cessation is still the best medicine. 
Postgrad Med 1998; 104: 56–62, 65–56, 71.
136 Gold PB, Rubey RN, Harvey RT. Naturalistic, self-assignment 
comparative trial of bupropion SR, a nicotine patch, or both for 
smoking cessation treatment in primary care. Am J Addict 2002; 
11: 315–31.
137 Shiffman S, Johnston JA, Khayrallah M, Elash CA, Gwaltney CJ, 
Paty JA, et al. The effect of bupropion on nicotine craving and withdrawal. Psychopharmacology (Berl) 2000; 148: 33–40.
138 Hughes JR, Stead LF, Lancaster T. Antidepressants for smoking 
cessation. Cochrane Database Syst Rev 2007; (1): CD000031.
139 Eisenberg MJ, Filion KB, Yavin D, Belisle P, Mottillo S, Joseph L, 
et al. Phamacotherapies for smoking cessation: a meta-analysis of 
randomized controlled trials. CMAJ 2008; 179: 135–44.
140 Kenny PJ, Paterson NE, Boutilier B, Semenova S, Harrison AA, 
Gasparini F, et al. Metastrophic glutamatergic 5 receptor antagonist 
MPEP decreased nicotine and cocaine self-administration but not 
nicotine and cocaine-induced facilitation of brain reward function 
in rats. Ann N Y Acad Sci 2003; 1003: 415–8.
141 Gass JT, Olive MF. Glutamatergic substrates of drug addiction 
and alcoholism. Biochem Pharmacol 2008; 75: 218–65.
142 Jones IW, Wonnacott S. Precise localization of alpha7 nicotinic 
acetylcholine receptors on glutamatergic axon terminals in the rat 
ventral tegmental area. J Neurosci 2004; 24: 11244–52.
143 Cadoni C, Di Chiara G. Differential changes in accumbens shell 
and core dopamine in behavioral sensitization to nicotine. Eur J 
Pharmacol 2000; 387: R23–5.
144 Booze RM, Welch MA, Wood ML, Billings KA, Apple SR, 
Mactutus CF. Behavioral sensitization following repeated intra-
venous nicotine administration: gender differences and gonadal 
hormones. Pharmacol Biochem Behav 1999; 64: 827–39.
145 Picciotto MR. Nicotine as a modulator of behavior: beyond the 
inverted U. Trends Pharmacol Sci 2003; 24: 493–9.
146 Liechti ME, Lhuillier L, Kaupmann K, Markou A. Metabotropic 
glutamate 2/3 receptors in the ventral tegmental area and the 
nucleus accumbens shell are involved in behaviors relating to 
nicotine dependence. J Neurosci 2007; 27: 9077–85.
147 Liechti ME, Markou A. Metabotropic glutamate 2/3 receptor 
activation induced reward deficits but did not aggravate brain 
reward deficits associated with spontaneous nicotine withdrawal 
in rats. Biochem Pharmacol 2007; 74: 1299–1307.
148 Liechti ME, Markou A. Interactive effects of the mGlu5 
receptor antagonist MPEP and the mGlu2/3 receptor antagonist 
LY341495 on nicotine self-administration and reward deficits 
associated with nicotine withdrawal in rats. Eur J Pharmacol 2007; 
554: 164–74.
149 Ferraguti F, Shigemoto R. Metabotropic glutamate receptors. 
Cell Tissue Res 2006; 326: 483–504.
150 Chiamulera C. Cue reactivity in nicotine and tobacco depend-
dence: a “multiple-action” model of nicotine as a primary 
reinforcement and as an enhancer of the effects of smoking-
associated stimuli. Brain Res Brain Res Rev 2005; 48: 74–97.
151 Paterson NE, Semenova S, Gasparini F, Markou A. The mGlu5 
antagonist MPEP decreased nicotine self-administration in rats 
and mice. Psychopharmacology (Berl) 2003; 167: 257–64.
152 Tessari M, Pilla M, Andreoli M, Hutcheson DM, Heidbreder 
CA. Antagonism at metabotropic glutamate 5 receptors inhibits 
nicotine- and cocaine-taking behaviours and prevents nicotine-
triggered relapse to nicotine-seeking. Eur J Pharmacol 2004; 499: 
121–33.
153 Paterson NE, Markou A. The metabotropic glutamate receptor 5 
antagonist MPEP decreased break points for nicotine, cocaine and 
food in rats. Psychopharmacology (Berl) 2005; 179: 255–61.
154 Bospalov AY, Dravolina OA, Sukhanov I, Zakharova E, Blokhina 
E, Zvartau E, et al. Metabotropic glutamate 5 receptor antagonist 
LY341495 on nicotine self-administration and reward deficits 
triggered relapse to nicotine-seeking. Eur J Pharmacol 2004; 554: 
121–33.
function and intravenous nicotine self-administration: role of the ventral tegmental area and central nucleus of the amygdala. Neuropsychopharmacology 2009; 34: 266–81.

Bormann J. Memantine is a potent blocker of N-methyl-D-aspartate (NMDA) receptor channels. Eur J Pharmacol 1989; 166: 591–2.

Blokhina EA, Kashkin VA, Zvartau EE, Danysh W, Bespalov AY. Effects of nicotinic and NMDA receptor channel blockers on intravenous cocaine and nicotine self-administration in mice. Eur Neuropsychopharmacology 2005; 15: 219–25.

Thuerauf N, Lunkenheimer J, Lunkenheimer B, Sperling W, Bleich S, Schlabeck M, et al. Memantine fails to facilitate partial cigarette deprivation in smokers—no role of Memantine in the treatment of nicotine dependency? J Neural Transm 2007; 114: 351–7.

Klitenstein MA, DeWitte P, Kalivas PW. Regulation of somatodendritic dopamine release in the ventral tegmental area by opioids and GABA: an in vivo microdialysis study. J Neurosci 1992; 12: 2623–32.

Cubells JF, Blanchard JS, Smith DM, Makman MH. In vivo action of enzyme-activated irreversible inhibitors of glutamic acid decarboxylase and gamma-aminobutyric acid transaminase in retina vs brain. J Pharmacol Exp Ther 1986; 238: 508–14.

Dewey SL, Brodie JD, Gerasimov M, Horan B, Gardner EL, Ashby CR Jr. A pharmacologic strategy for the treatment of nicotine addiction. Synapse 1999; 31: 76–86.

Paterson NE, Markou A. Increased GABA neurotransmission via nicotine receptor agonist and antagonists decreased brain stimulation reward in the rat. Neuropsychopharmacology 2001; 40: 676–85.

Urwyler S, Pozza MF, Lingenhoehl K, Mosbacher J, Lampert C, Froestl W, et al. N,N′-Dicyclopentyl-2-methylsulfanyl-5-nitro-pyrimidine-4,6-diamine (GS39783) and structurally related compounds: novel allosteric enhancers of gamma-aminobutyric acidB receptor function. J Pharmacol Exp Ther 2003; 307: 322–30.

Guery S, Floersheim P, Kaumann K, Froestl W. Syntheses and optimization of new GS39783 analogues as positive allosteric modulators of GABAA receptors. Bioorg Med Chem Lett 2007; 17: 6206–11.

Mombereau C, Lhuillier L, Kaufmann K, Cryan JF. GABAB receptor-positive modulation-induced blockade of the rewarding properties of nicotine is associated with a reduction in nucleus accumbens DeltaFosB accumulation. J Pharmacol Exp Ther 2007; 321: 172–7.

Paterson NE, Vlachou S, Guery S, Kaufmann K, Froestl W, Markou A. Positive modulation of GABAB receptors decreased nicotine self-administration and counteracted nicotine-induced enhancement of brain reward function in rats. J Pharmacol Exp Ther 2008; 326: 306–14.

Castane A, Berrendero F, Maldonado R. The role of the cannabinoid system in nicotine addiction. Pharmacol Biochem Behav 2005; 81: 381–6.

De Vries TJ, Schoffelmeer AN. Cannabinoid CB1 receptors control conditioned drug seeking. Trends Pharmacol Sci 2005; 26: 420–6.

Cohen C, Perrault G, Griebel G, Soubrie P. Nicotine-associated cues maintain nicotine-seeking behavior in rats several weeks after nicotine withdrawal: reversal by the cannabinoid (CB1) receptor antagonist, rimonabant (SR141716). Neuropsychopharmacology 2005; 30: 145–55.

Gonzalez S, Cascio MG, Fernandez-Ruiz J, Fezza F, Di Marzo V, Ramos JA. Changes in endocannabinoid contents in the brain of rats chronically exposed to nicotine, ethanol or cocaine. Brain Res 2002; 954: 73–81.

Castane A, Valjent E, Ledent C, Parmentier M, Maldonado R, Valverde O. Lack of CB1 cannabinoid receptors modifies nicotine behavioural responses, but not nicotine abstinence. Neuropharmacology 2002; 43: 857–67.

Cossu G, Ledent C, Fattore L, Imperato A, Bohme GA, Parmentier M, et al. Cannabinoid CB1 receptor knockout mice fail to self-administer morphine but not other drugs of abuse. Behav Brain Res 2001; 118: 61–5.

Cheer JF, Wassum KM, Sombers LA, Heien ML, Ariens JS, Aragona BJ, et al. Phasic dopamine release evoked by abused substances requires cannabinoid receptor activation. J Neurosci 2007; 27: 791–5.

Le Foll B, Forget B, Aubin HJ, Goldberg SR. Blocking cannabinoid CB1 receptors for the treatment of nicotine dependence: insights from pre-clinical and clinical studies. Addict Biol 2008; 13: 239–52.
Perio A, et al. SR147778 [5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-N-(1-piperidinyl)-1H-pyrazole-3-carboxamide], a new potent and selective antagonist of the CB1 cannabinoid receptor: biochemical and pharmacological characterization. J Pharmacol Exp Ther 2004; 310: 905–14.

Cohen C, Perrault G, Voltz C, Steinberg R, Soubrie P. SR141716, a central cannabinoid (CB1) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats. Behav Pharmacol 2002; 13: 451–63.

Le Foll B, Goldberg SR. Rimonabant, a CB1 antagonist, blocks nicotine-conditioned place preferences. Neuroreport 2004; 15: 2139–43.

Forget B, Hamon M, Thiebot MH. Cannabinoid CB1 receptors are involved in motivational effects of nicotine in rats. Psychopharmacology (Berl) 2005; 181: 722–34.

Rigotti NA, Gonzales D, Dale LC, Lawrence D, Chang Y. A randomized controlled trial of adding the nicotine patch to rimonabant for smoking cessation: efficacy, safety and weight gain. Addiction 2009; 104: 266–76.

Christensen R, Kristensen PK, Bartels EM, Bliddal H, Astrup AV. [A meta-analysis of the efficacy and safety of the anti-obesity agent Rimonabant]. Ugeskr Laeger 2007; 169: 4360–3.

Rucker D, Padwal R, Li SK, Curioni C, Lau DC. Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ 2007; 335: 1194–9.

Gatley SJ, Gifford AN, Volkow ND, Lan R, Makriyannis A. 123I-labeled AM251: a radioiodinated ligand which binds in vivo to mouse brain cannabinoid CB1 receptors. Eur J Pharmacol 1996; 307: 331–8.

Gatley SJ, Lan R, Pyatt B, Gifford AN, Volkow ND, Makriyannis A. Binding of the non-classical cannabinoid CP 55,940, and the diarylpyrazole AM251 to rodent brain cannabinoid receptors. Life Sci 1997; 61(14): PL 191–7.

Bhatti AS, Aydin C, Oztan O, Ma Z, Hall P, Tao R, et al. Effects of a cannabinoid receptor (CB) 1 antagonist AM251 on behavioral sensitization to nicotine in a rat model of novelty-seeking behavior: correlation with hippocampal 5-HT. Psychopharmacology (Berl) 2009; 203: 23–32.

Shoaib M. The cannabinoid antagonist AM251 attenuates nicotine self-administration and nicotine-seeking behaviour in rats. Neuropharmacology 2008; 54: 438–44.